Meiqi Shi

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

David R. Spigel, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2021 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17

Cisplatin-resistant lung cancer cell–derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100–5p-dependent manner

Xiaobing Qin, Shaorong Yu, Leilei Zhou et al. · International Journal of Nanomedicine · 2017 · 243 citations · Full text

Medicine, Molecular Biology, Oncology +17

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Zhijie Wang, Lin Wu, Baolan Li et al. · Journal of Clinical Oncology · 2022 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

Martin Reck, David Vicente, Tudor–Eliade Ciuleanu et al. · Annals of Oncology · 2018 · 103 citations · Full text

Medicine, Oncology, Pharmacology +17

Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial

Meiqi Shi, Hai‐Yan Tu, Cheng Huang et al. · Annals of Oncology · 2020 · 71 citations · Full text

Medicine, Oncology, Pharmacology +17